reference/4441971

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4441971

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	239
issn	0271-0749
issueIdentifier	2
pageRange	235-239
publicationName	Journal of Clinical Psychopharmacology
startingPage	235
bibliographicCitation	Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr;28(2):235–9. doi: 10.1097/jcp.0b013e31816774de. PMID: 18344738.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf8d8987204206ee1555945e30ea793a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32f9c38e22c0e3443901b22b4c25ad61 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a9117f4e8ec7bca776f09ae61b1bb6e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd15826efc7bfbfb0e20e72908085aff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e42a0e91c3e53700d86c6acad946c288 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24cb4c3cd68782b49c5d97842b24dcc7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_238c1f1b83977efe8c551ae20e43bef6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88f415ca4f00dd669ca615dff77358a5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a5476b2b513894fb21c3324dee725a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a00e95cc1156c2f2482728d25dfa6f4
date	200804
identifier	https://doi.org/10.1097/jcp.0b013e31816774de https://pubmed.ncbi.nlm.nih.gov/18344738
isPartOf	https://portal.issn.org/resource/ISSN/0271-0749 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4660
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
discusses	http://id.nlm.nih.gov/mesh/M0016884 http://id.nlm.nih.gov/mesh/M0026368 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0003316 http://id.nlm.nih.gov/mesh/M0499715
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D058825 http://id.nlm.nih.gov/mesh/D001008Q000188 http://id.nlm.nih.gov/mesh/D013449Q000627 http://id.nlm.nih.gov/mesh/D010879Q000627 http://id.nlm.nih.gov/mesh/D003866Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D009304Q000139 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D002214 http://id.nlm.nih.gov/mesh/D001008Q000523 http://id.nlm.nih.gov/mesh/D011569Q000706 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D013449Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D039721 http://id.nlm.nih.gov/mesh/D009325Q000139 http://id.nlm.nih.gov/mesh/D003866Q000523 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D010879Q000009 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D004244Q000139 http://id.nlm.nih.gov/mesh/D006261Q000139 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D000293
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7428 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1205d26ae74eb7ebcd012fd2decfc92 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6923 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7025 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11430856

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247147725 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3350 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129095671

Total number of triples: 67.